Synovis Life Technologies Granted Important FDA Indication and U.S. Patent for Veritas(R) Collagen Matrix

January 15, 2007 - 2:07 PM
Remodelable Biomaterial Made with Patented Process Shown to Minimize Post-Surgical Tissue Attachment Patent Issued for Method and Composition for Preventing Surgical Adhesions ST. PAUL, Minn., Jan. 11 /PRNewswire-FirstCall/ -- Synovis Life Technologies, Inc. (NASDAQ:SYNO) , has received clearance by the U.S. Food and Drug Administration (FDA) for an additional important indication for its Veritas(R) Collagen Matrix. Veritas has been shown to minimize internal tissue attachment, a common and painful post-surgical complication. Veritas is an implantable, biomedical material that provides a scaffold into which the body's own tissue can grow, effectively remodeling the implant to the host tissue. The FDA granted the additional indication after Synovis completed research in 2006 which examined adhesion formation and the tenacity of adhesions post surgery, and demonstrated that Veritas implants had minimal tissue attachment. Synovis received the original FDA 510(k) marketing clearance for Veritas in 2000. Additionally, Synovis holds a U.S. patent for the process to manufacture Veritas and was just issued another U.S. patent for "a method and composition for preventing surgical adhesions."
Read More